Evidence map›Paper›PMID 25194998›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2015

A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.

Anthony E Gregory, Barbara M Judy, Omar Qazi, Carla A Blumentritt, Katherine A Brown, Andrew M Shaw, Alfredo G Torres, Richard W Titball

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 89 citations in OpenAlex.

  1. Antibodies toMicroorganisms · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Vaccines · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Preparation and immunological properties of a nanovaccine againstIranian journal of basic medical sciences · 2021
    Article
  18. Current Advances inCells · 2020
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Anthony E GregorySchool of Biosciences, College of Life and Environmental Sciences, University of Exeter, Devon, UK.
Barbara M JudyDepartment of Pathology, University of TX Medical Branch, Galveston, USA.
Omar QaziDepartment of Chemistry, University of TX at Austin, Austin, USA.
Carla A BlumentrittDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA.
Katherine A BrownDepartment of Chemistry, University of TX at Austin, Austin, USA; Cavendish Laboratory, Department of Physics, University of Cambridge, UK.
Andrew M ShawSchool of Biosciences, College of Life and Environmental Sciences, University of Exeter, Devon, UK.
Alfredo G TorresDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA; Department of Pathology, University of TX Medical Branch, Galveston, USA. Electronic address: altorres@utmb.edu.
Richard W TitballSchool of Biosciences, College of Life and Environmental Sciences, University of Exeter, Devon, UK. Electronic address: R.W.Titball@exeter.ac.uk.
The University of Texas Medical Branch at Galveston · USUniversity of Exeter · GBThe University of Texas at Austin · USUniversity of Cambridge · GB

Funding

WRCE Nonhuman Primate CoreU54AI057156 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI WALKER, DAVID H · 2003 to 2013
$102.6M
Novel Molecular Recognition Reagents for Detection of Pathogenic BurkholderiaU01AI078008 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI BROWN, KATHERINE ANNE · 2008 to 2010
$1.8M
NIAID NIH HHS U01 AI078008NIAID NIH HHS U54 AI057156
6 · The paper itself

Abstract

Burkholderia mallei are Gram-negative bacteria, responsible for the disease glanders. B. mallei has recently been classified as a Tier 1 agent owing to the fact that this bacterial species can be weaponised for aerosol release, has a high mortality rate and demonstrates multi-drug resistance. Furthermore, there is no licensed vaccine available against this pathogen. Lipopolysaccharide (LPS) has previously been identified as playing an important role in generating host protection against Burkholderia infection. In this study, we present gold nanoparticles (AuNPs) functionalised with a glycoconjugate vaccine against glanders. AuNPs were covalently coupled with one of three different protein carriers (TetHc, Hcp1 and FliC) followed by conjugation to LPS purified from a non-virulent clonal relative, B. thailandensis. Glycoconjugated LPS generated significantly higher antibody titres compared with LPS alone. Further, they improved protection against a lethal inhalation challenge of B. mallei in the murine model of infection. FROM THE CLINICAL EDITOR: Burkholderia mallei is associated with multi-drug resistance, high mortality and potentials for weaponization through aerosol inhalation. The authors of this study present gold nanoparticles (AuNPs) functionalized with a glycoconjugate vaccine against this Gram negative bacterium demonstrating promising results in a murine model even with the aerosolized form of B. Mallei.

Indexed as

Administration, InhalationAnimalsBacterial VaccinesBurkholderia malleiDisease Models, AnimalGlandersGlycoconjugatesGoldHumansLipopolysaccharidesMetal NanoparticlesMiceBacterial VaccinesGlycoconjugatesGoldLipopolysaccharidesGlandersGlycoconjugateNanoparticles

Identifiers

PMID25194998
PMCPMC4330121
OpenAlexW2011188634

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.